MUGENBIO

The screening of prostate cancer is innacurate. The current standard relies on single protein biomarker developed 30 years ago.

We aim to replace this flawed and outdated test. We will achieve it by developing powerful diagnostic device capable to analyse 100+ protein biomarkers in 2 hours and for $300.

The higher resolution of molecular analysis will enable earlier and more accurate prostate cancer detection empowering oncologists and patients to fight with prostate cancer more effectively.